Welcome to Medications.com

Cephalon profit beats Street, shares rise - Guardian Unlimited

But sales of cancer pain drug Actiq fell 50 percent to $54.3 million as it faced competition from cheaper generic versions of the medicine. ...

http://www.guardian.co.uk/feedart... | Posted: Tue Feb 12 17:29:58 -0500 2008




© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com | Sleep Apnea